OMERS ADMINISTRATION Corp Has $917,000 Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

OMERS ADMINISTRATION Corp boosted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 19.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,684 shares of the medical equipment provider’s stock after buying an additional 1,443 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Zimmer Biomet were worth $917,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Dodge & Cox grew its position in shares of Zimmer Biomet by 12.0% in the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider’s stock valued at $2,019,480,000 after purchasing an additional 2,044,645 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Zimmer Biomet by 1.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider’s stock valued at $1,559,147,000 after buying an additional 176,337 shares in the last quarter. Van ECK Associates Corp increased its position in Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock worth $417,814,000 after buying an additional 218,688 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Zimmer Biomet by 398.7% during the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider’s stock worth $369,469,000 after buying an additional 2,796,372 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Zimmer Biomet by 7.6% in the fourth quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider’s stock valued at $250,367,000 after acquiring an additional 167,435 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at $915,379.20. This trade represents a 14.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.39% of the stock is owned by corporate insiders.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $96.78 on Friday. The company’s 50 day moving average price is $103.41 and its two-hundred day moving average price is $105.84. The firm has a market capitalization of $19.15 billion, a P/E ratio of 21.75, a P/E/G ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.92 and a fifty-two week high of $120.13. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The company had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. During the same quarter last year, the business posted $1.94 EPS. Zimmer Biomet’s revenue for the quarter was up 1.1% on a year-over-year basis. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.99%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 21.24%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Wells Fargo & Company dropped their price objective on shares of Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. Barclays cut their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Canaccord Genuity Group lowered their price objective on Zimmer Biomet from $115.00 to $101.00 and set a “hold” rating on the stock in a research note on Monday, May 12th. JMP Securities dropped their price objective on Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating for the company in a report on Wednesday, May 7th. Finally, Royal Bank of Canada reduced their target price on Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating on the stock in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $113.45.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.